Potential 99mTc radiopharmaceuticals for renal imaging: tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato)technetium(IV) cations.
A series of monocationic complexes of N-substituted-3-hydroxy-2-methyl-4-pyridinones labeled with technetium(IV)-99m have been evaluated in vivo as potential radiopharmaceuticals. The pyridinones have different substituents at the ring nitrogen atom: ethyl, i-propyl, i-butyl, benzyl, phenyl, p-methoxyphenyl, 3-butoxypropyl and cyclohexyl. Biodistribution studies of the 99mTc complexes have been carried out in rabbits and mice. High kidney uptake and retention of the radionuclide has been shown in rabbits and mice with the cationic complexes of 3-hydroxy-1-(p-methoxyphenyl)-2-methyl-4-pyridinone and 1-(cyclohexyl)-3-hydroxy-2-methyl-4-pyridinone. These 99mTcL3+ compounds appear to be morphologic renal agents.
Edwards
D S
DS
Du Pont Merck Pharmaceutical Company, Radiopharmaceutical Division, N. Billerica, MA 01862.
Liu
S
S
Lyster
D M
DM
Poirier
M J
MJ
Vo
C
C
Webb
G A
GA
Zhang
Z
Z
Orvig
C
C
D000818:Animals; D007668:Kidney / Q000000981:diagnostic imaging*; D051379:Mice; D011728:Pyridones / Q000493:pharmacokinetics; D011817:Rabbits; D011877:Radionuclide Imaging; D013667:Technetium; D014018:Tissue Distribution
D011728:Pyridones; D013667:Technetium